Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Dippoldiswalde – page 81

1 081 clinical trials in Dippoldiswalde, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Dippoldiswalde at a glance
1 081
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 081 trials in Dippoldiswalde

Open in trial search

Asthma

Not recruiting

Study on RPT193 for Adults with Moderate-to-Severe Asthma Partially Controlled by Inhaled Corticosteroids and Long-Acting Beta 2 Agonists

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Rapt Therapeutics Inc.

Dry eye+1

Not recruiting

Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Graves' disease

Not recruiting

Study on the Effects of Satralizumab for Patients with Moderate-to-Severe Thyroid Eye Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Dermatitis atopic

Not recruiting

Study on the Effects of LEO 138559 for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Interleukin 22 Receptor Subunit Alpha
  • Sponsor:Leo Pharma A/S

Study on Alteplase for Vision Recovery in Patients with Acute Central Retinal Artery Occlusion

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Pharma Mar S.A.

Study to Test BI 765845 for Patients with Heart Attack

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 765845
  • Sponsor:Boehringer Ingelheim Espana S.A.

Macular oedema+1

Not recruiting

Study on Ranibizumab Injections and Laser Treatment for Macular Edema in Central Retinal Vein Occlusion Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:Justus-Liebig-Universitaet Giessen

Pancreatic carcinoma+3

Not recruiting

Study on BI 907828 for Patients with Advanced Biliary Tract, Pancreatic, Lung, or Bladder Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Brigimadlin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Neoplasm

Not recruiting

Study of Favezelimab Combined with Pembrolizumab (MK-4280A) for Patients with Selected Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

IgA nephropathy

Not recruiting

Study on the Long-term Safety and Effectiveness of Sibeprenlimab for Patients with Immunoglobulin A Nephropathy (IgAN)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Dippoldiswalde

What the registry says about research in the country

01 Respiratory Disease Research

Ongoing clinical investigations focus on respiratory syncytial virus (RSV) infections in older adults, specifically targeting those aged 60 and above. The research examines immune responses and safety profiles of preventive interventions.

  • Vaccine Development
  • Immune Response Analysis
  • Senior Population Health

This extension study builds upon previous research to evaluate the effectiveness of revaccination strategies and long-term immune protection against RSV infections in elderly populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.